Posted from: Friday, December 01, 2017 - 02:14 PM - Present

New Formulation for Varubi

October 25, 2017 – The U.S. FDA has approved a new formulation for Varubi® (rolapitant), manufactured by Tesaro Pharmaceuticals. Varubi is indicated to prevent delayed nausea and vomiting caused by nausea-producing cancer chemotherapy when used in conjunction with dexamethasone and a 5-HT3 receptor antagonist. Varubi will now be available in an intravenous (IV) form, whereas it was previously available only as an oral tablet.

Varubi helps to prevent chemotherapy-induced nausea and vomiting (CINV) by blocking the receptors for human substance P/neurokinin 1 (NK-1). Recommended dosing is 166.5mg delivered over the course of 30 minutes no more than two hours before the administration of chemotherapy. Patients should not receive Varubi intravenous infusion if they have already had a dose within the previous two weeks.

Tesaro has already launched Varubi in intravenous form, available as single-dose vials that do not require reconstitution or dilution before use.


Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Wednesday, October 16, 2019 - 09:56 PM.